SOPHiA GENETICS and The University of Texas MD Anderson Cancer Center have entered into a collaboration to accelerate data-driven cancer care through new tools that can accurately analyze, interpret, and translate diagnostic results into clinical practice.
Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.
